Time-restricted eating: 12:12 → 14:10 → 16:8 — AU GP dosing protocol

What time-restricted eating is

Time-restricted eating (TRE) is a chrononutrition strategy in which all caloric intake occurs within a defined daily window (commonly 4–12 hours) and the remainder is a water-only or near-zero-calorie fast. It is distinct from alternate-day fasting (24-hour cycles), 5:2 (two low-calorie days), and prolonged fasting (beyond 36 hours).

Window notation — the first number is eating hours, the second is fasting hours. 12:12 (12 hours eating, 12 fasting), 14:10, 16:8 (most studied), 18:6. Anything under 6 hours eating is research-only.

Early TRE vs late TRE: early = window finishes by mid-afternoon (e.g. 7 am–3 pm); late = window starts after noon (e.g. 12 pm–8 pm). Early aligns intake with peak insulin sensitivity and β-cell responsiveness (Manoogian 2022 Endocr Rev).

TRE is a lifestyle protocol, not a TGA-listed therapy. Its best framing is as a scaffolding tool that helps a subset of patients eat less and align meals to circadian phase.

A. Core clinical — the AU general practice dosing protocol

Who it is for

Patient profile	Suitability	Preferred window	Notes
Adult, overweight or obese, no eating disorder history	Good	14:10 → 16:8	Earlier window favoured for metabolic outcomes
Type 2 diabetes, metformin only, HbA1c below 8%	Good	12:12 → 14:10	Recheck HbA1c at 12 weeks
Type 2 diabetes on insulin or sulfonylurea	Caution	12:12 only; CDE review first	Pre-emptive dose reduction; hypoglycaemia plan
Metabolic syndrome / MASLD / NAFLD	Good	10-h window	Wilkinson 2020 model
Shift worker	Conditional	Anchor window to biological day	Avoid eating in biological night
Pre-menopausal woman	Conditional	12:12 or 14:10	Track menses; avoid under 14-h fasting
Adolescent	Avoid	—	Eating disorder risk; growth requirements
Pregnancy or lactation	Contraindicated	—	Under-feeding risk
Type 1 diabetes	Contraindicated	—	Insulin-dosing complexity; DKA risk
Any restrictive eating disorder history	Contraindicated	—	Re-activates restriction–binge cycle
BMI below 19 or weight loss not the goal	Contraindicated	—	Caloric deficit harms
Frailty or sarcopenia, aged over 70	Contraindicated (usually)	—	Protein distribution for muscle preservation
On GLP-1 RA with nausea	Caution	12:12 only	Compounded under-eating risk

Contraindications — hard stops

Before prescribing TRE:

1. Any history of restrictive eating disorder (anorexia nervosa, bulimia nervosa, OSFED) or current binge-eating disorder with under-eating pattern — absolute contraindication
2. Pregnancy or lactation — absolute contraindication
3. Type 1 diabetes — absolute contraindication
4. Unstable type 2 diabetes on insulin or sulfonylurea without diabetes-educator review
5. Underweight (BMI below 19)
6. Active hypothalamic amenorrhoea or relative energy deficiency in sport (RED-S)
7. Adolescents — eating disorder risk, growth and energy needs

Concurrent GLP-1 receptor agonist with nausea: combined appetite suppression can drive unintended caloric deficit, lean-mass loss, and dehydration.

Dosing progression

1. Baseline (week 0): weight, waist, BP, HbA1c, fasting glucose and insulin (HOMA-IR), fasting lipids, LFTs, eGFR, menstrual diary (women), Eating Disorder Examination Questionnaire (EDE-Q) screen if any risk flag
2. Weeks 1–2 — 12:12: pick a 12-hour window aligned with the patient’s existing pattern (commonly 7 am–7 pm). No calorie counting. Permitted in fasting window: water, electrolytes, black tea/coffee, plain herbal tea
3. Weeks 3–4 — 14:10 if no red flags. Shorten the window by pushing dinner earlier (preferred) rather than skipping breakfast
4. Weeks 5–12 — 16:8 as the maintenance target only if tolerated, sleeping well, menses regular, no rebound bingeing. Earlier window (7 am–3 pm) outperforms later (12 pm–8 pm) where social structure permits
5. Reassess at 12 weeks — repeat biomarkers; decide continue / titrate down / discontinue

Biomarker tracking

Test	Baseline	Week 12	MBS item
Weight, BP, waist	✓	✓	in-consult
HbA1c	✓	✓	66551
Fasting glucose + insulin (HOMA-IR)	✓	✓	66500
Fasting lipids	✓	✓	66536
LFTs (MASLD / NAFLD)	✓	✓	66512
EDE-Q (if risk)	✓	✓	clinical
Menstrual diary (women)	continuous	continuous	clinical

Stop criteria

• Two or more binge episodes in 4 weeks → stop; consider eating disorder pathway
• Menstrual irregularity new onset in previously regular women → stop; review energy availability
• Lean-mass loss >5% on serial BIA / DXA → stop or shorten fast window; add resistance training and protein
• Symptomatic hypoglycaemia in diabetes → cease, review medications with diabetes educator
• Persistent fatigue, hair loss, cold intolerance → review for under-feeding, thyroid
• Pregnancy (planned or confirmed) → stop immediately

B. Evidence appraisal — what the trials actually show

Question	Position FOR	Position AGAINST	Evidence quality	Bottom line
Does TRE add to caloric restriction for weight loss?	Modest mechanistic benefit; eTRE outperforms later window (Jamshed 2022, Sutton 2018)	12-month RCT showed no benefit beyond matched caloric restriction (Liu 2022 NEJM); TREAT showed no advantage over consistent meal timing (Lowe 2020)	🟡 moderate	TRE scaffolds spontaneous caloric reduction, not a metabolic shortcut
Is the “metabolic switch” independent of weight loss?	Insulin sensitivity and BP improved in eTRF without weight change (Sutton 2018)	Effect sizes small; meta-analysis attributes most benefit to energy deficit + circadian alignment	🟡 moderate	Plausible but modest
Early TRE better than late TRE?	Multiple RCTs favour early window for insulin sensitivity, BP, weight (Jamshed 2022); 2025 network meta-analysis confirms direction	Social acceptability low; adherence drops	🟢 moderate-high	Where socially feasible, finish eating by mid-afternoon
Eating disorder risk?	Rule-based structure may be neutral or helpful in some	TRE prospectively associated with binge eating, compensatory behaviours, compulsive exercise (Ganson / Cuccolo 2022, Eat Behav); ANZAED flags any restrictive rule as potential trigger	🟢 signal (causality 🟡)	Screen before prescribing — any restrictive ED history = absolute contraindication
TRE during pregnancy or lactation	None — energy needs rise	Fetal harm plausible	🟢 against	Avoid
TRE plus GLP-1 receptor agonist	Theoretical synergy for satiety	Compounded appetite suppression → under-eating, dehydration, sarcopenia	🟡	Permit only after stable on GLP-1, no nausea, protein target met

Open questions:

• Long-term adherence and weight maintenance — almost all TRE RCTs are under 12 months; the one 12-month RCT was negative versus matched caloric restriction
• Macronutrient context — does TRE work better with Mediterranean / low-carb / high-protein patterns? Limited head-to-head data
• NHMRC Australian Dietary Guidelines update scheduled for 2026 — may include first formal AU position on intermittent fasting

C. Australian operations

• TGA status: TRE is a behavioural / lifestyle protocol — no TGA-listed product. Consumer apps (Zero, Lifesum, Simple, MyFast) are not medical devices
• Standard consultation billing: items 23 / 36 / 44 for initiation, titration, and review

GPCCMP — chronic-disease scaffold: GP Chronic Condition Management Plan items 965 (preparation) / 967 (review) — applies where TRE is one element of a plan for type 2 diabetes, obesity-with-comorbidity, metabolic syndrome, or MASLD. Funds five allied-health visits per calendar year (dietitian, exercise physiologist most relevant).

Mental Health Care Plan: items 2715 / 2717 where mood or mild disordered-eating comorbidity is present and the patient does not meet full eating disorder criteria.

Eating Disorder Plan (escalation): if TRE has tipped a patient into a formal eating disorder, transition to EDTMP items 90250–90257 (GP prepares plan). Plan unlocks up to 40 psychology + 20 dietetic sessions per 12-month period (InsideOut Institute reference).

Diabetes nurse educator / CDE review for all patients on insulin or sulfonylurea before initiating any TRE protocol — pre-emptive dose reduction (commonly 20–30%) is the safer default.

Medico-legal note: document indication, contraindications screened, eating disorder risk screen, baseline biomarkers, planned duration, and review date. A negative EDE-Q at baseline is the most defensible documentation if a patient later develops disordered eating.

D. Practical considerations

• Protein priority: a compressed window means fewer protein pulses — aim for ≥1.2 g/kg/day (≥1.6 g/kg/day if aged over 65 or sarcopenia risk), split into 2–3 doses of ≥30 g each
• Hydration in the fasting window: 2–3 L/day water plus electrolytes (sodium, potassium, magnesium); unsweetened tea and black coffee are permitted
• If the fast breaks: return to the planned window next day without compensatory restriction. Avoid “strict weekdays / relaxed weekends” patterns — this fuels binge cycles
• Mediterranean dietary pattern within the eating window is the best-evidenced macronutrient context
• Resistance training 2–3 times/week is mandatory if aged over 65 or on a GLP-1 receptor agonist — preserves lean mass in a caloric deficit
• Women of reproductive age: default to 12:12 or 14:10; track the menstrual cycle; stop if amenorrhoea, persistent fatigue, or hair loss

When to stop or escalate

• Eating disorder criteria met → Eating Disorder Plan pathway; cease TRE
• Menstrual irregularity or amenorrhoea → stop; review energy availability; consider functional hypothalamic amenorrhoea pathway
• Symptomatic hypoglycaemia → cease; medication review with diabetes educator
• Binge episodes, food preoccupation, body-checking → cease; EDE-Q + eating disorder pathway
• Lean-mass loss >5% on serial BIA → cease; add resistance training and protein; dietitian referral

What this article is and is not

This is general health information drawn from published TRE trial evidence and Australian general practice guidelines — RACGP/Diabetes Australia T2DM Handbook, ANZAED treatment principles, and NHMRC dietary guidelines. It is not personal medical advice and does not replace assessment and management by your own GP and treating clinicians. TRE is not suitable for everyone — the contraindications above are not exhaustive; individual clinical assessment is essential before starting.

For Australian consumer information: HealthDirect — intermittent fasting, NDSS (for diabetes), Butterfly Foundation — eating disorders.

For eating disorder crisis support: Butterfly Foundation Helpline 1800 33 4673. For acute mental-health crisis: Lifeline 13 11 14.

---

Sources cited

1. Liu D et al. — Calorie Restriction with or without Time-Restricted Eating (NEJM 2022)
2. Sutton EF et al. — Early Time-Restricted Feeding Improves Insulin Sensitivity without Weight Loss (Cell Metab 2018)
3. Lowe DA et al. — TREAT: Effects of Time-Restricted Eating on Weight Loss (JAMA Intern Med 2020)
4. Jamshed H et al. — Effectiveness of Early Time-Restricted Eating for Weight Loss (JAMA Intern Med 2022)
5. Wilkinson MJ et al. — Ten-Hour Time-Restricted Eating in Metabolic Syndrome (Cell Metab 2020)
6. Manoogian ENC et al. — Time-restricted Eating for Prevention and Management of Metabolic Diseases (Endocr Rev 2022)
7. Ganson KT, Cuccolo K et al. — Intermittent fasting and eating disorder behaviours in Canadian adolescents (Eat Behav 2022)
8. RACGP / Diabetes Australia — Management of Type 2 Diabetes: Handbook for General Practice (2024)
9. ANZAED — Eating disorder treatment principles and general clinical practice standards
10. NHMRC — Australian Dietary Guidelines review (delivery 2026)
11. InsideOut Institute — Medicare Eating Disorder item numbers
12. HealthDirect — Intermittent fasting